Searched for
ORAL INSULIN
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- No more painful insulin shots: Hyderabad company develops oral insulin spray for diabetesHyderabad-based NiedlFree Technologies has developed a needle-free oral insulin spray called Ozulin, offering a painless alternative for di...
- Novo Nordisk searches for tablet to replace insulin shotsThe company that reaped nearly 80% of its $16 billion sales from insulin products last year is hopeful for a regulatory approval for its fi...
- US drugmaker Bristol Myers Squibb out of Biocon’s oral insulin projectBMS had taken a wider decision to sell its entire diabetes franchise to British drug maker AstraZeneca, while narrowing its own focus on de...
- Biocon to further develop insulin TregopilBiocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...
- Biocon's oral insulin will take few more years to hit market: Kiran Mazumdar ShawBiocon my take a few more years to launch its oral insulin in the Indian market, said company's Chairman and Managing Director Kiran Mazumd...
- Biocon in insulin deal with US drug major Bristol-Myers SquibbBiocon has entered into a partnership for its oral insulin pill IN-105, giving BMS the option to exclusively develop and sell the product i...
- Biocon close to oral insulin deal with Bristol-Myers SquibbFour months after its partnership with Pfizer fell through, Biocon is now close to inking a deal with US-based biopharmaceuticals giant Bri...
- Expect a global partner for new oral insulin in 6 mnts: Biocon"But the multiple secondary endpoints on both efficacy and safety were met further strengthening the emerging profile of IN-105," the compa...
- Biocon to rope in global partner for oral insulinBiotechnology major Biocon on Tuesday that said the tests conducted for its experimental oral insulin, IN-105 , have not met their primary ...
- Very bullish on Glenmark: Aunali Rupani, ARM ResearchNext 5 years will see a big run up in all the pharma stocks in India especially R&D.
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
- Biocon to launch oral insulin drug by 2010Biotech company Biocon is planning to launch its oral insulin drug in India by 2010 and is targeting sales of Rs 500 crore from the domesti...
- Biocon to launch oral insulin drug by 2010Biotech company Biocon is planning to launch its oral insulin drug in India by 2010 and is targeting sales of Rs 500 crore from the domesti...
- Generex gets CDSCO nod for non-injectable insulinUS-based Generex Biotechnology Corporation on Friday said it has received approval from the Central Drugs Standards Control Organisation (C...
- First needle-free insulin soonBiotechnology company Shreya Lifesciences has entered into an in-licensing agreement with US-based Generex Biotechnology Corp to market Ora...
- Clinical trials for oral insulin to enter phase two: BioconAfter the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.
- UAS studies GM seeds for anti-diabetic drugUniversity of Agricultural Sciences (UAS), Bangalore is working on transgenic or genetically-modified groundnut and Colius Forscoli as an e...
Load More
